「survival」の検索結果

Generate professional clinical decision support (CDS) documents for pharmaceutical and clinical research settings, including patient cohort analyses (biomarker-stratified with outcomes) and treatment recommendation reports (evidence-based guidelines with decision algorithms). Supports GRADE evidence grading, statistical analysis (hazard ratios, survival curves, waterfall plots), biomarker integration, and regulatory compliance. Outputs publication-ready LaTeX/PDF format optimized for drug development, clinical research, and evidence synthesis.

日本語の概要は準備中です。原文の説明を表示しています。

Blender MCP expert for scene inspection, Python scripting, GLTF export, and material/animation extraction. Activate when: (1) using Blender MCP tools (get_scene_info, execute_python, screenshot, etc.), (2) writing Blender Python scripts for extraction or manipulation, (3) exporting scenes to GLTF/GLB for web (Three.js, R3F), (4) debugging material or texture export losses, (5) optimizing GLB files with gltf-transform, (6) using asset integrations (PolyHaven, Sketchfab, Hyper3D Rodin, Hunyuan3D). Covers critical export gotchas, material mapping survival, texture optimization pipeline, headless CLI patterns, and known failure modes.

日本語の概要は準備中です。原文の説明を表示しています。

Use when a task needs the judgment of a Biostatistician — designing a clinical trial's sample size and analysis plan, choosing a survival-analysis or censoring-aware method, preparing a DSMB safety readout, or judging whether a trial's efficacy claim survives ITT vs. per-protocol scrutiny.

日本語の概要は準備中です。原文の説明を表示しています。

Audit manufacturing predictive maintenance systems for OPC-UA/MQTT sensor data pipelines, time-series storage retention, ML model lifecycle (training-serving skew, drift detection, retraining triggers), MTBF/MTTF/MTTR reliability calculations, Weibull survival analysis.

日本語の概要は準備中です。原文の説明を表示しています。

Statistical methods for biology and medicine — study design, hypothesis testing, regression, and survival analysis.

日本語の概要は準備中です。原文の説明を表示しています。

Computes sample size and power for clinical trials including continuous, binary, and time-to-event endpoints; superiority, non-inferiority, and equivalence designs; FDA 2016 non-inferiority margin selection with M1/M2 framework; Schoenfeld 1981 and Lakatos 1988 for survival; Schuirmann TOST and 80-125% bioequivalence; minimum clinically important difference (MCID) vs δ distinction. Use when justifying trial size in protocol or SAP per CONSORT 2025 item 16a.

日本語の概要は準備中です。原文の説明を表示しています。

Calculate the Maryland Aggregate Pathology Index (MAPI) on a deceased donor procurement kidney biopsy to predict graft survival and decide single vs dual vs discard allocation. Trigger when a clinician asks "what's the MAPI score", "interpret donor kidney biopsy", "should I use this marginal kidney", "MAPI cutoff for transplant", "procurement biopsy scoring", or has histology results from a deceased donor kidney and needs an objective grading.

日本語の概要は準備中です。原文の説明を表示しています。

A comprehensive toolkit for AI agents operating under budget constraints.

日本語の概要は準備中です。原文の説明を表示しています。

Context-survival and proactive-iteration extensions. Always-on. Covers Working Buffer Protocol, Compaction Recovery, Relentless Resourcefulness, and Self-Improvement Guardrails.

日本語の概要は準備中です。原文の説明を表示しています。

Computes sample size and power for clinical trials including continuous, binary, and time-to-event endpoints; superiority, non-inferiority, and equivalence designs; FDA 2016 non-inferiority margin selection with M1/M2 framework; Schoenfeld 1981 and Lakatos 1988 for survival; Schuirmann TOST and 80-125% bioequivalence; minimum clinically important difference (MCID) vs δ distinction. Use when justifying trial size in protocol or SAP per CONSORT 2025 item 7.

日本語の概要は準備中です。原文の説明を表示しています。

Statistical modeling — linear/logistic/ordinal/Poisson regression, ANOVA, Kruskal-Wallis, chi-square, Mann-Whitney, Cox survival, spline fits (R `ns()`), odds ratios, Cohen's d, F-statistic, p-value computation. Specializes in clinical-trial AE analysis (SDTM DM/AE), severity ordinal regression, and per-feature stat workflows.

日本語の概要は準備中です。原文の説明を表示しています。

Builds diagnostic and prognostic classifiers on omics feature matrices with regularized logistic regression, random forest, and gradient-boosted trees, handling the p>>n regime, batch shortcut learning, class imbalance, and probability calibration. Use when building a classifier from expression, methylation, or variant data, choosing an algorithm for high-dimensional small-n data, or diagnosing a suspiciously perfect AUC. For unbiased evaluation see machine-learning/model-validation; for feature selection see machine-learning/biomarker-discovery; for time-to-event outcomes see machine-learning/survival-analysis.

日本語の概要は準備中です。原文の説明を表示しています。

End-to-end clinical trial analysis workflow from CDISC SDTM/ADaM loading through ICH E9(R1) estimand-driven primary analysis to CONSORT 2025 regulatory-compliant reporting. Covers data preparation, FDA 2023 marginal vs conditional logistic regression, categorical tests with Boschloo, modern HTE/subgroup methods, missing-data sensitivity (MMRM, reference-based MI, Permutt tipping point), graphical multiplicity (Bretz-Maurer), survival analysis (Cox/RMST/competing risks) when applicable, and Table 1. Use when performing a complete analysis of clinical trial data.

日本語の概要は準備中です。原文の説明を表示しています。

Dose-response / concentration-response curve fitting — IC50, EC50, Hill slope, Emax/Emin efficacy, and relative potency from paired concentration vs response data (enzyme/cell assays, drug screening, agonist/antagonist pharmacology). Fits the 4-parameter logistic (Hill sigmoidal) model. Use when you have concentrations + responses and need a potency value, to compare two compounds' potency, or to judge curve quality. NOT for image-derived dose-response (use tooluniverse-image-analysis) and NOT for survival/regression (use tooluniverse-statistical-modeling).

日本語の概要は準備中です。原文の説明を表示しています。

Computes sample size and power for clinical trials including continuous, binary, and time-to-event endpoints; superiority, non-inferiority, and equivalence designs; FDA 2016 non-inferiority margin selection with M1/M2 framework; Schoenfeld 1981 and Lakatos 1988 for survival; Schuirmann TOST and 80-125% bioequivalence; minimum clinically important difference (MCID) vs δ distinction. Use when justifying trial size in protocol or SAP per CONSORT 2025 item 7.

日本語の概要は準備中です。原文の説明を表示しています。

Computes sample size and power for clinical trials including continuous, binary, and time-to-event endpoints; superiority, non-inferiority, and equivalence designs; FDA 2016 non-inferiority margin selection with M1/M2 framework; Schoenfeld 1981 and Lakatos 1988 for survival; Schuirmann TOST and 80-125% bioequivalence; minimum clinically important difference (MCID) vs δ distinction. Use when justifying trial size in protocol or SAP per CONSORT 2025 item 7.

日本語の概要は準備中です。原文の説明を表示しています。

Complete Three.js building system with spatial indexing, structural physics, and multiplayer networking. Use for survival/crafting games, sandbox games, multiplayer construction, or any 3D building mechanics.

日本語の概要は準備中です。原文の説明を表示しています。

Generate professional clinical decision support (CDS) documents for pharmaceutical and clinical research settings, including patient cohort analyses (biomarker-stratified with outcomes) and treatment recommendation reports (evidence-based guidelines with decision algorithms). Supports GRADE evidence grading, statistical analysis (hazard ratios, survival curves, waterfall plots), biomarker integration, and regulatory compliance. Outputs publication-ready LaTeX/PDF format optimized for drug development, clinical research, and evidence synthesis.

日本語の概要は準備中です。原文の説明を表示しています。